AI assistant
Genmab — Remuneration Information 2011
Jan 18, 2011
Preview isn't available for this file type.
Download source fileCopenhagen, Denmark; January 18, 2011-Pursuant to Section 28a of the Danish
Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on
transactions by managerial employees and their related parties involving Genmab
shares and related instruments, as follows:
Name: Nedjad Losic
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Warrants
Transaction: Grant
Trading date: December 9, 2010
Market: NASDAQ OMX Copenhagen A/S
Number: 1,000
Value: DKK 37,290
The exercise price for each warrant is DKK 66.60. Each warrant entitles the
owner to subscribe one share of nominally DKK 1. On the basis of an exercise
price of DKK 66.60 and by application of the Black-Scholes formula, the average
value of each warrant can be calculated as DKK 37.29 based on an interest rate
of 1.8948% and the historical volatility of Genmab A/S shares calculated at
64.15%.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: [email protected]
This Stock Exchange Release contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section “Risk Management” in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®;
HuMax-EGFr™;HuMax-IL8™;HuMax-TAC™;HuMax-HepC™; HuMax-CD38™; HuMax-TF™;
HuMax-Her2™; HuMax-Wnt™; HuMax-cMet™ and UniBody®are all trademarks of Genmab
A/S. Arzerra®is a trademark of GlaxoSmithKline.
Stock Exchange Release no. 1
CVR no. 2102 3884